Pilot Study Indicates Potential Intermittent Exotropia Improvements With Luminopia Software

Binocular treatment for children with intermittent exotropia (IXT) via Luminopia’s self-titled prescription digital therapeutic may improve eye movement control, according to preliminary results from a pilot study.¹

“While this is a small pilot, these findings are exciting because they suggest that dichoptic therapy delivered via Luminopia may improve control in children with IXT,” Evan Silverstein, MD, associate professor at Virginia Commonwealth University Medical School and lead author of the study, said in a statement. “This lays the groundwork for Luminopia to potentially become the first nonsurgical, FDA-cleared treatment for IXT.”¹

Luminopia is the first digital therapeutic for any neurovisual disorder to be approved by the FDA, having received its first indication for amblyopia in children. The program allows parents to choose television shows and movies to watch from a broad selection of educational content; after selection, dual-acting algorithms modify the video in real time with a virtual reality (VR) headset to promote weaker eye usage, encouraging the patient’s brain to combine input from both eyes.^1,2

Notably, Luminopia is a software-only digital therapeutic designed for use with commercially available Head-Mounted Displays (HMDs) that are compatible with the software application. The treatment is intended as an adjunct to full-time refractive correction, such as glasses, which should be worn under the HMD during therapy.¹

Luminopia was cleared by the FDA for children aged 4 to under 13 years after validation through data from a series of clinical trials and a real-world registry. The final approval was based on evidence from a phase 3 randomized controlled trial with a primary efficacy outcome of change in amblyopic eye visual acuity from baseline at 12 weeks. During the trial, visual acuity was measured by masked examiners, and safety was evaluated via the frequency and severity of study-related adverse events.²

The trial investigators randomly assigned 51 patients to receive treatment and 54 to a comparison group. By the 12-week point, amblyopic-eye visual acuity improved by 1.8 lines in the treatment group, compared with 0.8 lines in the comparison group. A planned interim analysis highlighted a significant difference between groups of 1 line, and the study was stopped early for success. No serious adverse events were recorded.²

The present pilot study included 10 patients, all children aged 4 to 7 years, with unilateral IXT. Patients were prescribed 1 hour per day of Luminopia therapy 6 days a week for 3 months. The patients exhibited an adherence rate of 50% or more. Control scores and stereopsis measurements were taken at baseline, after treatment, and after a 3-month washout period.¹

Silverstein and colleagues noted several key findings from the pilot study, including a significant improvement from baseline in distance-control scores. The patients exhibited a mean of 2.9 at baseline, which rose to 1.7 after 3 months (P = .01). Additionally, these improvements did not regress following the 3-month washout, indicating a possible sustained benefit. Stereoacuity also improved during the course of the study.¹

“This pilot study offers promising early data and underscores the potential of dichoptic therapy to transform care for children with intermittent exotropia,” Scott Xiao, founder and chief executive officer of Luminopia, said in a statement. “The findings also validate the broader therapeutic potential of our platform in treating conditions at the intersection of the visual system and the brain.”¹

References

1. Luminopia shows promise in improving control of intermittent exotropia in pilot study. Luminopia. March 25, 2026. Accessed March 25, 2026. https://www.prnewswire.com/news-releases/luminopia-shows-promise-in-improving-control-of-intermittent-exotropia-in-pilot-study-302724282.html

2. Xiao S, Angjeli E, Wu HC, et al; Luminopia Pivotal Trial Group. Randomized controlled trial of a dichoptic digital therapeutic for amblyopia. Ophthalmology. 2022;129(1):77-85. doi:10.1016/j.ophtha.2021.09.001